GRP78 is an appealing candidate for immunotherapeutic intervention as it is overexpressed at all myeloma stages and increased in patients with disease progression, especially in those patients with drug-resistance and extramedullary disease. The gene discussed is HSPA5; the disease is plasma cell myeloma.